Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 31
Filter
1.
Neurology ; 99(13): e1335-e1344, 2022 09 27.
Article in English | MEDLINE | ID: mdl-35918161

ABSTRACT

BACKGROUND AND OBJECTIVES: Restricting follow-up assessment of both interventional and observational studies to patients who provide informed consent introduces relevant selection bias-particularly by underrepresenting patients with neurologic communication deficits and impaired capacity to consent. Many patients who are initially unable to give consent may be willing to do so after recovery. Informing patients on study purposes and procedures with offering them the option of nonparticipation but not requesting explicit consent is called "opt-out" approach. We investigated whether an opt-out strategy yields meaningful follow-up rates in an acute stroke registry with an embedded controlled study. METHODS: The citywide Berlin-SPecific Acute Treatment in Ischemic or hAemorrhagic Stroke With Long Term Follow-up (B-SPATIAL) registry was designed to provide reliable information on process indicators and outcomes of specific acute stroke treatments to inform health care providers about quality of care and best practice strategies including the effects of a mobile stroke unit implementation. Because this information was regarded of high public interest, Berlin data protection authorities permitted data sampling without prior informed consent, using instead follow-up assessment on an "opt-out" basis. Patients were included if they had neurologic symptoms at ambulance or hospital arrival within 6 hours of onset and had a final diagnosis of stroke or TIA. Information on data collection and outcome assessment was sent by letter to patients 1 month before follow-up. RESULTS: From February 1, 2017, to January 31, 2020, a total of 10,597 patients were assessed. Thirty-one (0.3%) patients declined any data use, whereas 578 (5.5%) opted out of follow-up assessment. Of those not opting out (n = 9,988), functional outcome (modified Rankin Scale) was collected in 8,330 patients (83.4%) and vital status in 9,741 patients (97.5%). We received no complaints regarding data collection procedures. DISCUSSION: Opt-out-based follow-up collection offers a way to achieve high follow-up rates along with respecting patients' preferences.


Subject(s)
Stroke , Data Collection , Follow-Up Studies , Humans , Quality of Health Care , Registries , Stroke/diagnosis , Stroke/therapy
4.
J Neurol ; 269(1): 470-480, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34718884

ABSTRACT

AIMS: We aimed to analyze prevalence and predictors of NOAC off-label under-dosing in AF patients before and after the index stroke. METHODS: The post hoc analysis included 1080 patients of the investigator-initiated, multicenter prospective Berlin Atrial Fibrillation Registry, designed to analyze medical stroke prevention in AF patients after acute ischemic stroke. RESULTS: At stroke onset, an off-label daily dose was prescribed in 61 (25.5%) of 239 NOAC patients with known AF and CHA2DS2-VASc score ≥ 1, of which 52 (21.8%) patients were under-dosed. Under-dosing was associated with age ≥ 80 years in patients on rivaroxaban [OR 2.90, 95% CI 1.05-7.9, P = 0.04; n = 29] or apixaban [OR 3.24, 95% CI 1.04-10.1, P = 0.04; n = 22]. At hospital discharge after the index stroke, NOAC off-label dose on admission was continued in 30 (49.2%) of 61 patients. Overall, 79 (13.7%) of 708 patients prescribed a NOAC at hospital discharge received an off-label dose, of whom 75 (10.6%) patients were under-dosed. Rivaroxaban under-dosing at discharge was associated with age ≥ 80 years [OR 3.49, 95% CI 1.24-9.84, P = 0.02; n = 19]; apixaban under-dosing with body weight ≤ 60 kg [OR 0.06, 95% CI 0.01-0.47, P < 0.01; n = 56], CHA2DS2-VASc score [OR per point 1.47, 95% CI 1.08-2.00, P = 0.01], and HAS-BLED score [OR per point 1.91, 95% CI 1.28-2.84, P < 0.01]. CONCLUSION: At stroke onset, off-label dosing was present in one out of four, and under-dosing in one out of five NOAC patients. Under-dosing of rivaroxaban or apixaban was related to old age. In-hospital treatment after stroke reduced off-label NOAC dosing, but one out of ten NOAC patients was under-dosed at discharge. CLINICAL TRIAL REGISTRATION: NCT02306824.


Subject(s)
Atrial Fibrillation , Brain Ischemia , Stroke , Administration, Oral , Aged, 80 and over , Anticoagulants/therapeutic use , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapy , Berlin , Brain Ischemia/complications , Brain Ischemia/drug therapy , Humans , Off-Label Use , Prospective Studies , Registries , Stroke/complications , Stroke/drug therapy
5.
BMC Neurol ; 21(1): 283, 2021 Jul 19.
Article in English | MEDLINE | ID: mdl-34281522

ABSTRACT

BACKGROUND: Most spontaneous subarachnoid hemorrhages (SAH) occur unexpectedly and independently of classical risk factors. In the light of increasing climate variability and change, we investigated weather and rapid weather changes as possible short-term risk factors for SAH. METHODS: Seven hundred ninety one patients admitted to three major hospitals in Germany for non-traumatic SAH with a determinable onset of SAH symptoms were included in this hospital-based, case-crossover study. The effects of atmospheric pressure, relative air humidity, and ambient temperature and their 24 h changes on the onset of SAH under temperate climate conditions were estimated. RESULTS: There was no association between the risk of SAH and 24 h weather changes, mean daily temperature or mean relative air humidity in the overall population. For every 11.5 hPa higher mean daily atmospheric pressure, the risk of SAH increased by 15% (OR 1.15, 95% confidence interval (CI) 1.01-1.30) in the entire study population with a lag time of three days. CONCLUSION: Our results suggest no relevant association between 24 h-weather changes or absolute values of ambient temperature and relative humidity and the risk of SAH. The medical significance of the statistically weak increase in SAH risk three days after exposure to high atmospheric pressure is unclear. However, as the occurrence of stable high-pressure systems will increase with global warming and potentially affect SAH risk, we call for confirming studies in different geographical regions to verify our observations.


Subject(s)
Atmospheric Pressure , Humidity , Subarachnoid Hemorrhage/epidemiology , Temperature , Adult , Aged , Cross-Over Studies , Female , Germany/epidemiology , Humans , Male , Middle Aged , Retrospective Studies
6.
JAMA ; 322(14): 1392-1403, 2019 10 08.
Article in English | MEDLINE | ID: mdl-31593272

ABSTRACT

Importance: The association of surgical hematoma evacuation with clinical outcomes in patients with cerebellar intracerebral hemorrhage (ICH) has not been established. Objective: To determine the association of surgical hematoma evacuation with clinical outcomes in cerebellar ICH. Design, Setting, and Participants: Individual participant data (IPD) meta-analysis of 4 observational ICH studies incorporating 6580 patients treated at 64 hospitals across the United States and Germany (2006-2015). Exposure: Surgical hematoma evacuation vs conservative treatment. Main Outcomes and Measures: The primary outcome was functional disability evaluated by the modified Rankin Scale ([mRS] score range: 0, no functional deficit to 6, death) at 3 months; favorable (mRS, 0-3) vs unfavorable (mRS, 4-6). Secondary outcomes included survival at 3 months and at 12 months. Analyses included propensity score matching and covariate adjustment, and predicted probabilities were used to identify treatment-related cutoff values for cerebellar ICH. Results: Among 578 patients with cerebellar ICH, propensity score-matched groups included 152 patients with surgical hematoma evacuation vs 152 patients with conservative treatment (age, 68.9 vs 69.2 years; men, 55.9% vs 51.3%; prior anticoagulation, 60.5% vs 63.8%; and median ICH volume, 20.5 cm3 vs 18.8 cm3). After adjustment, surgical hematoma evacuation vs conservative treatment was not significantly associated with likelihood of better functional disability at 3 months (30.9% vs 35.5%; adjusted odds ratio [AOR], 0.94 [95% CI, 0.81 to 1.09], P = .43; adjusted risk difference [ARD], -3.7% [95% CI, -8.7% to 1.2%]) but was significantly associated with greater probability of survival at 3 months (78.3% vs 61.2%; AOR, 1.25 [95% CI, 1.07 to 1.45], P = .005; ARD, 18.5% [95% CI, 13.8% to 23.2%]) and at 12 months (71.7% vs 57.2%; AOR, 1.21 [95% CI, 1.03 to 1.42], P = .02; ARD, 17.0% [95% CI, 11.5% to 22.6%]). A volume range of 12 to 15 cm3 was identified; below this level, surgical hematoma evacuation was associated with lower likelihood of favorable functional outcome (volume ≤12 cm3, 30.6% vs 62.3% [P = .003]; ARD, -34.7% [-38.8% to -30.6%]; P value for interaction, .01), and above, it was associated with greater likelihood of survival (volume ≥15 cm3, 74.5% vs 45.1% [P < .001]; ARD, 28.2% [95% CI, 24.6% to 31.8%]; P value for interaction, .02). Conclusions and Relevance: Among patients with cerebellar ICH, surgical hematoma evacuation, compared with conservative treatment, was not associated with improved functional outcome. Given the null primary outcome, investigation is necessary to establish whether there are differing associations based on hematoma volume.


Subject(s)
Cerebellar Diseases/surgery , Cerebral Hemorrhage/surgery , Conservative Treatment , Hematoma/surgery , Aged , Cerebellar Diseases/therapy , Cerebellum/surgery , Cerebral Hemorrhage/therapy , Female , Hematoma/therapy , Humans , Male , Observational Studies as Topic , Treatment Outcome
7.
Europace ; 21(11): 1621-1632, 2019 Nov 01.
Article in English | MEDLINE | ID: mdl-31397475

ABSTRACT

AIMS: The Berlin Atrial Fibrillation Registry was designed to analyse oral anticoagulation (OAC) prescription in patients with atrial fibrillation (AF) and acute ischaemic stroke. METHODS AND RESULTS: This investigator-initiated prospective multicentre registry enrolled patients at all 16 stroke units located in Berlin, Germany. The ongoing telephone follow-up is conducted centrally and will cover 5 years per patient. Within 2014 and 2016, 1080 patients gave written informed consent and 1048 patients were available for analysis. Median age was 77 years [interquartile range (IQR) 72-83], 503 (48%) patients were female, and 254 (24%) had a transient ischaemic attack (TIA). Overall, 470 (62%) out of 757 patients with known AF and a (pre-stroke) CHA2DS2-VASc ≥ 1 were anticoagulated at the time of stroke. At hospital discharge, 847 (81.3%) of 1042 patients were anticoagulated. Thereof 710 (68.1%) received a non-vitamin K-dependent oral anticoagulant (NOAC) and 137 (13.1%) a vitamin K antagonist (VKA). Pre-stroke intake of a NOAC [odds ratio (OR) 15.6 (95% confidence interval, 95% CI 1.97-122)] or VKA [OR 0.04 (95% CI 0.02-0.09)], an index TIA [OR 0.56 (95% CI 0.34-0.94)] rather than stroke, heart failure [OR 0.49 (95% CI 0.26-0.93)], and endovascular thrombectomy at hospital admission [OR 12.9 (95% CI 1.59-104)] were associated with NOAC prescription at discharge. Patients' age or AF type had no impact on OAC or NOAC use, respectively. CONCLUSION: About 60% of all registry patients with known AF received OAC at the time of stroke or TIA. At hospital discharge, more than 80% of AF patients were anticoagulated and about 80% of those were prescribed a NOAC.


Subject(s)
Anticoagulants/administration & dosage , Atrial Fibrillation/drug therapy , Brain Ischemia/prevention & control , Registries , Acute Disease , Administration, Oral , Adolescent , Adult , Aged , Aged, 80 and over , Atrial Fibrillation/complications , Berlin/epidemiology , Brain Ischemia/epidemiology , Brain Ischemia/etiology , Female , Follow-Up Studies , Humans , Incidence , Male , Middle Aged , Prognosis , Prospective Studies , Young Adult
8.
Stroke ; 50(6): 1392-1402, 2019 06.
Article in English | MEDLINE | ID: mdl-31092170

ABSTRACT

Background and Purpose- Given inconclusive studies, it is debated whether clinical and imaging characteristics, as well as functional outcome, differ among patients with intracerebral hemorrhage (ICH) related to vitamin K antagonists (VKA) versus non-vitamin K antagonist (NOAC)-related ICH. Notably, clinical characteristics according to different NOAC agents and dosages are not established. Methods- Multicenter observational cohort study integrating individual patient data of 1328 patients with oral anticoagulation-associated ICH, including 190 NOAC-related ICH patients, recruited from 2011 to 2015 at 19 tertiary centers across Germany. Imaging, clinical characteristics, and 3-months modified Rankin Scale (mRS) outcomes were compared in NOAC- versus VKA-related ICH patients. Propensity score matching was conducted to adjust for clinically relevant differences in baseline parameters. Subgroup analyses were performed regarding NOAC agent, dosing and present clinically relevant anticoagulatory activity (last intake <12h/24h or NOAC level >30 ng/mL). Results- Despite older age in NOAC patients, there were no relevant differences in clinical and hematoma characteristics between NOAC- and VKA-related ICH regarding baseline hematoma volume (median [interquartile range]: NOAC, 14.7 [5.1-42.3] mL versus VKA, 16.4 [5.8-40.6] mL; P=0.33), rate of hematoma expansion (NOAC, 49/146 [33.6%] versus VKA, 235/688 [34.2%]; P=0.89), and the proportion of patients with unfavorable outcome at 3 months (mRS, 4-6: NOAC 126/179 [70.4%] versus VKA 473/682 [69.4%]; P=0.79). Subgroup analyses revealed that NOAC patients with clinically relevant anticoagulatory effect had higher rates of intraventricular hemorrhage (n/N [%]: present 52/109 [47.7%] versus absent 9/35 [25.7%]; P=0.022) and hematoma expansion (present 35/90 [38.9%] versus absent 5/30 [16.7%]; P=0.040), whereas type of NOAC agent or different NOAC-dosing regimens did not result in relevant differences in imaging characteristics or outcome. Conclusions- If effectively anticoagulated, there are no differences in hematoma characteristics and functional outcome among patients with NOAC- or VKA-related ICH. Clinical Trial Registration- URL: https://www.clinicaltrials.gov . Unique identifier: NCT03093233.


Subject(s)
Anticoagulants/administration & dosage , Cerebral Hemorrhage/drug therapy , Fibrinolytic Agents/administration & dosage , Vitamin K/antagonists & inhibitors , Administration, Oral , Aged , Aged, 80 and over , Cerebral Hemorrhage/diagnostic imaging , Cerebral Hemorrhage/epidemiology , Female , Germany/epidemiology , Humans , Male , Retrospective Studies
9.
J Neurol Neurosurg Psychiatry ; 90(7): 783-791, 2019 07.
Article in English | MEDLINE | ID: mdl-30992334

ABSTRACT

OBJECTIVE: To determine the occurrence of intracranial haemorrhagic complications (IHC) on heparin prophylaxis (low-dose subcutaneous heparin, LDSH) in primary spontaneous intracerebral haemorrhage (ICH) (not oral anticoagulation-associated ICH, non-OAC-ICH), vitamin K antagonist (VKA)-associated ICH and non-vitamin K antagonist oral anticoagulant (NOAC)-associated ICH. METHODS: Retrospective cohort study (RETRACE) of 22 participating centres and prospective single-centre study with 1702 patients with VKA-associated or NOAC-associated ICH and 1022 patients with non-OAC-ICH with heparin prophylaxis between 2006 and 2015. Outcomes were defined as rates of IHC during hospital stay among patients with non-OAC-ICH, VKA-ICH and NOAC-ICH, mortality and functional outcome at 3 months between patients with ICH with and without IHC. RESULTS: IHC occurred in 1.7% (42/2416) of patients with ICH. There were no differences in crude incidence rates among patients with VKA-ICH, NOAC-ICH and non-OAC-ICH (log-rank p=0.645; VKA-ICH: 27/1406 (1.9%), NOAC-ICH 1/130 (0.8%), non-OAC-ICH 14/880 (1.6%); p=0.577). Detailed analysis according to treatment exposure (days with and without LDSH) revealed no differences in incidence rates of IHC per 1000 patient-days (LDSH: 1.43 (1.04-1.93) vs non-LDSH: 1.32 (0.33-3.58), conditional maximum likelihood incidence rate ratio: 1.09 (0.38-4.43); p=0.953). Secondary outcomes showed differences in functional outcome (modified Rankin Scale=4-6: IHC: 29/37 (78.4%) vs non-IHC: 1213/2048 (59.2%); p=0.019) and mortality (IHC: 14/37 (37.8%) vs non-IHC: 485/2048 (23.7%); p=0.045) in disfavour of patients with IHC. Small ICH volume (OR: volume <4.4 mL: 0.18 (0.04-0.78); p=0.022) and low National Institutes of Health Stroke Scale (NIHSS) score on admission (OR: NIHSS <4: 0.29 (0.11-0.78); p=0.014) were significantly associated with fewer IHC. CONCLUSIONS: Heparin administration for venous thromboembolism (VTE) prophylaxis in patients with ICH appears to be safe regarding IHC among non-OAC-ICH, VKA-ICH and NOAC-ICH in this observational cohort analysis. Randomised controlled trials are needed to verify the safety and efficacy of heparin compared with other methods for VTE prevention.


Subject(s)
Cerebral Hemorrhage/complications , Heparin/therapeutic use , Venous Thromboembolism/prevention & control , Aged , Aged, 80 and over , Cerebral Hemorrhage/mortality , Female , Humans , Male , Prospective Studies , Retrospective Studies , Venous Thromboembolism/etiology , Venous Thromboembolism/mortality
10.
IEEE Trans Vis Comput Graph ; 25(5): 2040-2049, 2019 05.
Article in English | MEDLINE | ID: mdl-30762553

ABSTRACT

Fish Tank Virtual Reality (FTVR) displays create a compelling 3D spatial effect by rendering to the perspective of the viewer with head-tracking. Combining FTVR with a spherical display enhances the 3D experience with unique properties of the spherical screen such as the enclosing shape, consistent curved surface, and borderless views from all angles around the display. The ability to generate a strong 3D effect on a spherical display with head-tracked rendering is promising for increasing user's performance in 3D tasks. An unanswered question is whether these natural affordances of spherical FTVR displays can improve spatial perception in comparison to traditional flat FTVR displays. To investigate this question, we conducted an experiment to see whether users can perceive the depth and size of virtual objects better on a spherical FTVR display compared to a flat FTVR display on two tasks. Using the spherical display, we found significantly that users had 1cm depth accuracy compared to 6.5cm accuracy using the flat display on a depth-ranking task. Likewise, their performance on a size-matching task was also significantly better with the size error of 2.3mm on the spherical display compared to 3.1mm on the flat display. Furthermore, the perception of size-constancy is stronger on the spherical display than the flat display. This study indicates that the natural affordances provided by the spherical form factor improve depth and size perception in 3D compared to a flat display. We believe that spherical FTVR displays have potential as a 3D virtual environment to provide better task performance for various 3D applications such as 3D designs, scientific visualizations, and virtual surgery.


Subject(s)
Computer Graphics , Depth Perception/physiology , Imaging, Three-Dimensional/methods , Size Perception/physiology , Virtual Reality , Adolescent , Adult , Animals , Female , Fishes , Humans , Male , Young Adult
11.
Neuroepidemiology ; 51(3-4): 207-215, 2018.
Article in English | MEDLINE | ID: mdl-30205396

ABSTRACT

BACKGROUND: To evaluate if weather or changes in weather are risk factors for Bell's palsy (BP) as exposure to draught of cold air has been popularly associated with the occurrence of BP. METHODS: Using a multicenter hospital-based case-crossover study, we analyzed the association between ambient temperature, atmospheric pressure, relative air humidity or their 24 h changes and the risk for BP in 825 patients or subgroups. RESULTS: One day following a 24 h increase in atmospheric pressure of more than 6 hPa, the risk for BP increased by 35% (OR 1.35; 95% CI 1.03-1.78) in the overall population. The risk for BP more than doubled in patients with diabetes mellitus after rapid variations in ambient temperature, independent of the direction (temperature decrease > 2.25°C; OR 2.15; 95% CI 1.08-4.25; temperature increase between 0.75 and 2.25°C; OR 2.88; 95% CI 1.63-5.10). CONCLUSIONS: Our findings support the hypothesis of an association between certain weather conditions and the risk for BP with acute changes in atmospheric pressure and ambient temperature as the main risk factors. Additionally, contrasting results for risk of BP after temperature changes in the diabetic and non-diabetic subgroups support the paradigm of a diabetic facial palsy as a distinct disease entity.


Subject(s)
Bell Palsy/epidemiology , Bell Palsy/etiology , Cold Temperature , Weather , Adult , Aged , Atmospheric Pressure , Case-Control Studies , Cross-Over Studies , Female , Humans , Male , Middle Aged , Risk Factors
12.
Eur Heart J ; 39(19): 1709-1723, 2018 05 14.
Article in English | MEDLINE | ID: mdl-29529259

ABSTRACT

Aims: Evidence is lacking regarding acute anticoagulation management in patients after intracerebral haemorrhage (ICH) with implanted mechanical heart valves (MHVs). Our objective was to investigate anticoagulation reversal and resumption strategies by evaluating incidences of haemorrhagic and thromboembolic complications, thereby defining an optimal time-window when to restart therapeutic anticoagulation (TA) in patients with MHV and ICH. Methods and results: We pooled individual patient-data (n = 2504) from a nationwide multicentre cohort-study (RETRACE, conducted at 22 German centres) and eventually identified MHV-patients (n = 137) with anticoagulation-associated ICH for outcome analyses. The primary outcome consisted of major haemorrhagic complications analysed during hospital stay according to treatment exposure (restarted TA vs. no-TA). Secondary outcomes comprised thromboembolic complications, the composite outcome (haemorrhagic and thromboembolic complications), timing of TA, and mortality. Adjusted analyses involved propensity-score matching and multivariable cox-regressions to identify optimal timing of TA. In 66/137 (48%) of patients TA was restarted, being associated with increased haemorrhagic (TA = 17/66 (26%) vs. no-TA = 4/71 (6%); P < 0.01) and a trend to decreased thromboembolic complications (TA = 1/66 (2%) vs. no-TA = 7/71 (10%); P = 0.06). Controlling treatment crossovers provided an incidence rate-ratio [hazard ratio (HR) 10.31, 95% confidence interval (CI) 3.67-35.70; P < 0.01] in disadvantage of TA for haemorrhagic complications. Analyses of TA-timing displayed significant harm until Day 13 after ICH (HR 7.06, 95% CI 2.33-21.37; P < 0.01). The hazard for the composite-balancing both complications, was increased for restarted TA until Day 6 (HR 2.51, 95% CI 1.10-5.70; P = 0.03). Conclusion: Restarting TA within less than 2 weeks after ICH in patients with MHV was associated with increased haemorrhagic complications. Optimal weighing-between least risks for thromboembolic and haemorrhagic complications-provided an earliest starting point of TA at Day 6, reserved only for patients at high thromboembolic risk.


Subject(s)
Anticoagulants/adverse effects , Anticoagulants/therapeutic use , Cerebral Hemorrhage/drug therapy , Hemorrhage/chemically induced , Thromboembolism/chemically induced , Aged , Anticoagulants/administration & dosage , Atrial Fibrillation/complications , Cerebral Hemorrhage/complications , Drug Administration Schedule , Female , Heart Valve Prosthesis , Humans , Male , Middle Aged , Retrospective Studies , Risk Assessment , Treatment Outcome , Vitamin K/antagonists & inhibitors
13.
Neuroimage ; 115: 1-6, 2015 Jul 15.
Article in English | MEDLINE | ID: mdl-25913700

ABSTRACT

Brain morphology varies during the course of the menstrual cycle, with increases in individual gray matter volume at the time of ovulation. This study implemented our previously presented BrainAGE framework to analyze short-term neuroanatomical changes in healthy young women due to hormonal changes during the menstrual cycle. The BrainAGE approach determines the complex multidimensional aging pattern within the whole brain by applying established kernel regression methods to anatomical brain MRIs. The "Brain Age Gap Estimation" (i.e., BrainAGE) score is then calculated as the difference between chronological age and estimated brain age. Eight women (21-31 years) completed three to four MRI scans during their menstrual cycle (i.e., at (t1) menses, (t2) time of ovulation, (t3) midluteal phase, (t4) next menses). Serum levels of estradiol and progesterone were evaluated at each scanning session. Individual BrainAGE scores significantly differed during the course of the menstrual cycle (p<0.05), with a significant decrease of -1.3 years at ovulation (p<0.05). Moreover, higher estradiol levels significantly correlated with lower BrainAGE scores (r=-0.42, p<0.05). In future, the BrainAGE approach may serve as a sensitive as well as easily implementable tool to further explore the short-term and maybe long-term effects of hormones on brain plasticity and its modulating effects in lifestyle-related diseases and dementia.


Subject(s)
Brain/anatomy & histology , Brain/growth & development , Menstrual Cycle/physiology , Adult , Aging/physiology , Brain/physiology , Estradiol/blood , Female , Humans , Magnetic Resonance Imaging , Neuronal Plasticity/physiology , Ovulation/physiology , Progesterone/blood , Young Adult
14.
JAMA ; 313(8): 824-36, 2015 Feb 24.
Article in English | MEDLINE | ID: mdl-25710659

ABSTRACT

IMPORTANCE: Although use of oral anticoagulants (OACs) is increasing, there is a substantial lack of data on how to treat OAC-associated intracerebral hemorrhage (ICH). OBJECTIVE: To assess the association of anticoagulation reversal and blood pressure (BP) with hematoma enlargement and the effects of OAC resumption. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study at 19 German tertiary care centers (2006-2012) including 1176 individuals for analysis of long-term functional outcome, 853 for analysis of hematoma enlargement, and 719 for analysis of OAC resumption. EXPOSURES: Reversal of anticoagulation during acute phase, systolic BP at 4 hours, and reinitiation of OAC for long-term treatment. MAIN OUTCOMES AND MEASURES: Frequency of hematoma enlargement in relation to international normalized ratio (INR) and BP. Incidence analysis of ischemic and hemorrhagic events with or without OAC resumption. Factors associated with favorable (modified Rankin Scale score, 0-3) vs unfavorable functional outcome. RESULTS: Hemorrhage enlargement occurred in 307 of 853 patients (36.0%). Reduced rates of hematoma enlargement were associated with reversal of INR levels <1.3 within 4 hours after admission (43/217 [19.8%]) vs INR of ≥1.3 (264/636 [41.5%]; P < .001) and systolic BP <160 mm Hg at 4 hours (167/504 [33.1%]) vs ≥160 mm Hg (98/187 [52.4%]; P < .001). The combination of INR reversal <1.3 within 4 hours and systolic BP of <160 mm Hg at 4 hours was associated with lower rates of hematoma enlargement (35/193 [18.1%] vs 220/498 [44.2%] not achieving these values; OR, 0.28; 95% CI, 0.19-0.42; P < .001) and lower rates of in-hospital mortality (26/193 [13.5%] vs 103/498 [20.7%]; OR, 0.60; 95% CI, 0.37-0.95; P = .03). OAC was resumed in 172 of 719 survivors (23.9%). OAC resumption showed fewer ischemic complications (OAC: 9/172 [5.2%] vs no OAC: 82/547 [15.0%]; P < .001) and not significantly different hemorrhagic complications (OAC: 14/172 [8.1%] vs no OAC: 36/547 [6.6%]; P = .48). Propensity-matched survival analysis in patients with atrial fibrillation who restarted OAC showed a decreased HR of 0.258 (95% CI, 0.125-0.534; P < .001) for long-term mortality. Functional long-term outcome was unfavorable in 786 of 1083 patients (72.6%). CONCLUSIONS AND RELEVANCE: Among patients with OAC-associated ICH, reversal of INR <1.3 within 4 hours and systolic BP <160 mm Hg at 4 hours were associated with lower rates of hematoma enlargement, and resumption of OAC therapy was associated with lower risk of ischemic events. These findings require replication and assessment in prospective studies. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01829581.


Subject(s)
Anticoagulants/adverse effects , Blood Pressure , Cerebral Hemorrhage/chemically induced , Hematoma/physiopathology , Aged , Anticoagulants/administration & dosage , Atrial Fibrillation/complications , Atrial Fibrillation/drug therapy , Blood Pressure/drug effects , Cerebral Hemorrhage/physiopathology , Disease Progression , Female , Hematoma/etiology , Hemorrhage/chemically induced , Humans , International Normalized Ratio , Ischemia/chemically induced , Kaplan-Meier Estimate , Logistic Models , Male , Middle Aged , Retrospective Studies , Stroke/etiology , Treatment Outcome
15.
Clin Neurol Neurosurg ; 113(5): 430-3, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21371818

ABSTRACT

Here, we demonstrate a first case of tick-borne encephalitis (TBE) associated with an isolated reversible splenial corpus callosum lesion (IRSL) and highlight the wide range of different clinical entities in which such alterations have been observed. A 42-year-old man showed fever, cephalgia and mild disturbance of coordination and gait. Diagnosis was ascertained by slight CSF-pleiocytosis and positive TBE-IgG as well as by positive intrathekal specific antibody index on follow-up. MRI demonstrated a single ovoid hyperintensity in T2 and DWI with reduction in ADC in the splenium of corpus callosum which was abrogated in follow-up after 6 weeks. Most entities of IRSL presented with excellent prognosis, including our novel case of TBE. We discuss different possible pathomechanisms and the so far unexplained propensity of the splenium for such alterations. Clinicians should be familiar with this phenomenon to avoid unnecessary diagnostic or therapeutic efforts.


Subject(s)
Corpus Callosum/pathology , Encephalitis, Tick-Borne/pathology , Acyclovir/therapeutic use , Adult , Anti-Bacterial Agents/therapeutic use , Antiviral Agents/therapeutic use , Ataxia/etiology , Ceftriaxone/therapeutic use , Diffusion Magnetic Resonance Imaging , Encephalitis, Tick-Borne/diagnosis , Encephalitis, Tick-Borne/therapy , Fever/etiology , Gait Disorders, Neurologic/etiology , Headache/etiology , Humans , Image Processing, Computer-Assisted , Immunoglobulin G/analysis , Magnetic Resonance Imaging , Male , Neck Pain/etiology
16.
PLoS One ; 6(2): e14655, 2011 Feb 04.
Article in English | MEDLINE | ID: mdl-21326603

ABSTRACT

BACKGROUND: There is increasing evidence for hormone-dependent modification of function and behavior during the menstrual cycle, but little is known about associated short-term structural alterations of the brain. Preliminary studies suggest that a hormone-dependent decline in brain volume occurs in postmenopausal, or women receiving antiestrogens, long term. Advances in serial MR-volumetry have allowed for the accurate detection of small volume changes of the brain. Recently, activity-induced short-term structural plasticity of the brain was demonstrated, challenging the view that the brain is as rigid as formerly believed. METHODOLOGY/PRINCIPAL FINDINGS: We used MR-volumetry to investigate short-term brain volume changes across the menstrual cycle in women or a parallel 4 week period in men, respectively. We found a significant grey matter volume peak and CSF loss at the time of ovulation in females. This volume peak did not correlate with estradiol or progesterone hormone levels. Men did not show any significant brain volume alterations. CONCLUSIONS/SIGNIFICANCE: These data give evidence of short-term hormone-dependent structural brain changes during the menstrual cycle, which need to be correlated with functional states and have to be considered in structure-associated functional brain research.


Subject(s)
Brain/anatomy & histology , Menstrual Cycle/physiology , Adult , Body Fluids/metabolism , Body Fluids/physiology , Brain/diagnostic imaging , Estradiol/analysis , Estradiol/blood , Female , Humans , Magnetic Resonance Imaging , Male , Menstrual Cycle/blood , Menstrual Cycle/cerebrospinal fluid , Organ Size/physiology , Ovulation/blood , Ovulation/cerebrospinal fluid , Ovulation/physiology , Progesterone/analysis , Progesterone/blood , Radiography , Sex Characteristics , Young Adult
17.
Epileptic Disord ; 12(2): 136-7, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20488781

ABSTRACT

We report the case of a patient with idiopathic generalized epilepsy who ten years after the onset of his epilepsy also developed recurring nocturnal paroxysmal episodes reminiscent of his seizure semiology. Video monitoring and polysomnography revealed episodes of nocturnal groaning. Escalation of antiepileptic treatment was avoided.


Subject(s)
Epilepsy, Generalized/physiopathology , Parasomnias/physiopathology , Phonation/physiology , Electroencephalography , Follow-Up Studies , Humans , Male , Parasomnias/diagnosis , Polysomnography , Recurrence , Signal Processing, Computer-Assisted , Sleep, REM/physiology , Snoring/physiopathology , Sound Spectrography , Video Recording , Young Adult
18.
Epilepsy Res ; 89(2-3): 355-9, 2010 May.
Article in English | MEDLINE | ID: mdl-20236802

ABSTRACT

The clinical differentiation between stroke and seizure is usually straightforward but postictal neurological deficits can be mistaken for stroke in case no detailed medical history is available. Up to now, the imaging findings of Todd's paresis are not well described. This case report demonstrates that postictal paresis can be accompanied by a reversible global hemispheric hypoperfusion as measured with perfusion MRI indicating transient but profound cerebrovascular dysfunction in postictal paresis. Extensive postictal perfusion changes must be discriminated from emerging stroke to avoid potentially harmful therapy like thrombolysis. Further investigations are warranted to clarify the role of cerebrovascular dysfunction in the pathophysiology of postictal paresis.


Subject(s)
Brain Ischemia/physiopathology , Brain/blood supply , Hemiplegia/diagnosis , Hemiplegia/etiology , Seizures/complications , Adult , Brain/pathology , Brain Ischemia/diagnosis , Diagnosis, Differential , Humans , Hypesthesia/diagnosis , Hypesthesia/etiology , Magnetic Resonance Angiography , Magnetic Resonance Imaging , Male , Stroke/diagnosis
19.
Sleep ; 33(3): 327-33, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20337190

ABSTRACT

STUDY OBJECTIVES: Arteriosclerosis related stenosis in the carotid bulb causes autonomic imbalance, likely due to carotid chemoreceptor and baroreceptor dysfunction. The latter are associated with increased cerebrovascular and cardiovascular mortality. Chemoreceptor and baroreceptor dysfunction is also involved in the origin of central sleep apnea syndrome (CSA) in different clinical entities. We hypothesized that CSA is associated with stenosis of the internal carotid artery (ICA). The mechanism of this association is an autonomic imbalance induced by stenosis-mediated chemoreceptor and baroreceptor dysfunction. DESIGN: Cross-sectional prospective study. SETTING: University-based tertiary referral sleep clinic and research center. PATIENTS: Fifty-nine patients with various degrees of asymptomatic extracranial ICA (elCA) (n = 49) and intracranial ICA (ilCA) stenosis (n = 10) were investigated. INTERVENTIONS: Polysomnography to detect CSA and analysis of spontaneous heart rate variability (HRV) to detect autonomic imbalance. MEASUREMENTS AND RESULTS: CSA occurred in 39% of the patients with elCA stenosis but was absent in patients with ilCA stenosis. CSA was present in patients with severe elCA stenosis of > or = 70% on one side. Independent predictors for CSA were severity of stenosis, asymmetric distribution of stenosis between both elCA and autonomic imbalance, namely a decrease of parasympathetic tone. The specific constellation of HRV-parameters indicated increased chemoreceptor sensitivity and impaired baroreflex sensitivity. CONCLUSIONS: CSA indicates autonomic dysfunction in patients with asymptomatic elCA stenosis. Detection of CSA may help to identify asymptomatic patients with an increased risk of cerebrovascular or cardiovascular events who particularly benefit from carotid revascularization.


Subject(s)
Autonomic Nervous System Diseases/diagnosis , Autonomic Nervous System Diseases/physiopathology , Carotid Stenosis/physiopathology , Cerebral Infarction/diagnosis , Cerebral Infarction/physiopathology , Myocardial Infarction/diagnosis , Myocardial Infarction/physiopathology , Sleep Apnea, Central/diagnosis , Sleep Apnea, Central/physiopathology , Adult , Aged , Aged, 80 and over , Baroreflex/physiology , Carotid Artery, External/physiopathology , Carotid Artery, Internal/physiopathology , Carotid Stenosis/diagnosis , Female , Heart Rate/physiology , Humans , Male , Polysomnography , Risk , Young Adult
20.
Clin Neurol Neurosurg ; 112(4): 265-74, 2010 May.
Article in English | MEDLINE | ID: mdl-20089351

ABSTRACT

Gait disturbances are frequent in older patients and lead to immobility, falls, and increased mortality. In gerontoneurologic patients a higher prevalence of risk factors for gait disturbances and falls has to be attributed due to neurodegenerative diseases, dementia, delirium, or psychotropic medication. The potential of neurological expertise to contribute to the evaluation and treatment of falls and gait disorders in geriatric patients is still not fully exploited. Sometimes a fall can be an index event to the diagnosis of the underlying disorder. This review, therefore, focuses on the relationship between falls, gait, and neurological diagnosis. It helps to find the correct diagnosis of the underlying disease as one major step in the management of gait disorders and fall prevention. From a pragmatic point of view falls can be classified according to loss or preservation of consciousness. Gait disturbances should be differentiated into gait disorders with and without cognitive impairment. Although gait impairments are influenced by multifactorial parameters, this differentiation may help to find a diagnosis and also to initiate an appropriate, disease-specific therapy. In addition, every fall patient has to be analyzed individually according to his individual risk factors, which all can potentially be influenced to improve mobility and to reduce falls.


Subject(s)
Accidental Falls/statistics & numerical data , Aged/physiology , Gait Disorders, Neurologic/epidemiology , Accidental Falls/prevention & control , Cognition Disorders/complications , Dementia/complications , Gait Disorders, Neurologic/diagnosis , Gait Disorders, Neurologic/prevention & control , Humans , Neurodegenerative Diseases/complications , Neurologic Examination
SELECTION OF CITATIONS
SEARCH DETAIL